recombinant human papillomavirus virus type 6/11 bivalent vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
1
Earliest trial started Mar 1, 2016 (NCT02710851)
Timeline
Indications
Approved for
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant human papillomavirus virus type 6/11 bivalent vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05415345 | Phase 4 | Oct 25, 2021 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Government of China |
| NCT04508309 | Phase 3 | Dec 31, 2020 | Agogo Presbyterian Hospital, Ghana, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., International Center for Diarrheal Disease Research, Leidos, PATH, The EMMES Corporation |
| NCT05383625 | Phase 3 | Sep 1, 2020 | Zagazig University |
| NCT02710851 | Phase 2 | Mar 1, 2016 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Government of China, University of Michigan, Xiamen University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | For profit | 3 | 1 | 3 | 2016 |
| Government of China | Government | 2 | 0 | 2 | 2016 |
| Agogo Presbyterian Hospital, Ghana | Academic/Hospital | 1 | 0 | 1 | 2020 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Leidos | For profit | 1 | 0 | 1 | 2020 |
| PATH | Academic/Hospital | 1 | 1 | 1 | 2020 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2020 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Xiamen University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Zagazig University | Academic/Hospital | 1 | 1 | 1 | 2020 |
10 organizations
Page 1 / 1